Supplement Stack for Focus: Evidence-Based Protocol for Cognitive Performance

A well-designed supplement stack for focus doesn’t start with stimulants — it starts with the metabolic substrates your brain needs to sustain attention over hours, not minutes. The compounds reviewed here have been tested in randomized controlled trials for cognitive endpoints in healthy adults: working memory, reaction time, executive function, and sustained attention. The distinction matters. Caffeine and similar stimulants produce acute effects that often generate tolerance or rebound within days. The stack below — built around NMN, ashwagandha, and lion’s mane — operates at the level of neuronal energy metabolism, stress-axis modulation, and neurotrophic signaling. The mechanisms are slower, but they compound over weeks and months.

The Evidence Base

Three compound categories have published human RCT data for cognitive outcomes:

NAD+ precursors (NMN): Yoshino et al. (2021) found improved skeletal muscle insulin sensitivity in postmenopausal women with prediabetes at 250 mg NMN/day — a metabolic endpoint directly relevant to cognition, since insulin resistance is correlated with hippocampal impairment. Igarashi et al. (2022) in healthy older men found elevated blood NAD+ metabolites and alterations in muscle function with chronic NMN supplementation. Irie et al. (2020) confirmed oral NMN safety and significant increases in NAD+ metabolite levels in blood. Gomes et al. (2013) established the foundational mechanism: declining NAD+ disrupts nuclear-mitochondrial communication, a pathway active in neurons. It’s worth stating plainly: cognition hasn’t been the primary endpoint in most published NMN human trials. Several ongoing RCTs are now specifically targeting cognitive endpoints. The mechanistic case is strong; the direct clinical evidence in healthy adults is still accumulating. The full NMN and brain health article details what NAD+ does for neurons specifically.

KSM-66 ashwagandha: Choudhary et al. (2017) is the most directly applicable trial — 300 mg KSM-66 twice daily for 8 weeks in 50 healthy adults showed statistically significant improvements in immediate memory, general memory, executive function, sustained attention, and information processing speed versus placebo. Effect sizes were modest (Cohen’s d = 0.3–0.5) but consistent across all cognitive measures. Chandrasekhar et al. (2012) established the cortisol-reduction effect (14–27% reduction versus placebo) that partly explains ashwagandha’s cognitive effects — cortisol chronically elevated above physiological range impairs prefrontal cortex function through multiple pathways. See the full review of ashwagandha memory and cognition trials for effect size detail.

Lion’s mane (Hericium erinaceus): Mori et al. (2009) tested 1,000 mg/day in adults with mild cognitive impairment and found significant improvements on the Hasegawa Dementia Scale at weeks 8, 12, and 16 versus placebo. A 2023 University of Queensland trial found a single acute dose improved reaction time and working memory in healthy young adults, though this needs replication. The evidence base in healthy populations is still thin — the mechanism (hericenone/erinacine stimulation of NGF synthesis) is sound, but human data in non-impaired adults is limited.

The Mechanism: Neuronal Energy and Cognitive Performance

The brain consumes approximately 20% of resting metabolic energy despite comprising roughly 2% of body mass. The prefrontal cortex — which governs working memory, sustained attention, and executive function — is metabolically the most demanding brain region and the first to show impairment under energy deficit or oxidative stress.

The following table compares the core ingredients commonly found in evidence-based focus stacks:

Ingredient	Mechanism	Evidence Level	Typical Dose
Caffeine	Adenosine receptor antagonist; increases dopamine/norepinephrine	High	100–200 mg
L-Theanine	GABA modulation; reduces caffeine jitteriness	High (with caffeine)	200 mg
Lion's Mane (Hericium)	NGF stimulation; supports neuroplasticity	Moderate	500–1000 mg extract
Bacopa monnieri	Antioxidant; cholinergic modulation; long-term memory consolidation	Moderate	300–450 mg (45% bacosides)
Alpha-GPC	Acetylcholine precursor; enhances working memory	Moderate	300–600 mg
Rhodiola rosea	Adaptogen; reduces mental fatigue under stress	Moderate	200–400 mg (3% rosavins)
Phosphatidylserine	Cell membrane fluidity; cortisol regulation	Moderate	100–300 mg

NAD+ serves two functions critical to cognitive performance:

1. Mitochondrial ATP generation: NAD+ is the primary electron carrier in Complex I of the electron transport chain. When NAD+ availability falls — as it does progressively from the 30s onward, and faster under metabolic stress — neurons generate ATP less efficiently. The subjective experience is cognitive fatigue, slower processing speed, and reduced working memory capacity during demanding tasks.
2. Sirtuin-mediated neuroprotection: SIRT1 (NAD+-dependent) regulates BDNF gene expression and mitochondrial biogenesis in neurons. BDNF (brain-derived neurotrophic factor) is required for synaptic plasticity and long-term memory formation. As NAD+ declines, SIRT1 activity falls, BDNF expression decreases, and synaptic plasticity is impaired — directly reducing learning capacity and working memory ceiling.

Ashwagandha’s cognitive mechanism is distinct: HPA axis modulation. Withanolides in KSM-66 suppress stress-induced ACTH secretion, reducing cortisol output. This is relevant to cognitive performance because cortisol chronically elevated above normal range impairs glutamate-mediated long-term potentiation in the hippocampus and reduces prefrontal cortex function through GABAergic inhibition. Cortisol reduction, in this model, removes a functional ceiling on cognitive performance that no amount of additional substrate can address.

Lion’s mane compounds stimulate synthesis of nerve growth factor (NGF) via MAPK and NF-κB signaling. NGF supports maintenance and growth of cholinergic neurons in the basal forebrain — the cells that provide acetylcholine to the cortex and hippocampus, mediating attention and memory encoding. The cholinergic system is the most directly implicated in working memory and focused attention.

Building the Stack: Foundation and Amplification Layers

This protocol is organized in two tiers. Tier 1 addresses metabolic prerequisites. Tier 2 amplifies a functioning foundation. Adding Tier 2 without Tier 1 in place produces diminishing returns because the underlying limiting factors haven’t been resolved.

Tier 1 — Foundation (weeks 1–4, establish before adding anything):

• NMN 500–1,000 mg/day, taken in the morning: NAMPT (the rate-limiting NAD+ biosynthesis enzyme) peaks in early morning in synchrony with the circadian clock. Morning dosing aligns NMN supplementation with the window of highest endogenous NAD+ synthesis activity. Bio:sudo NMN 1000mg delivers 1,000 mg per serving, cGMP certified with third-party COA available.
• Magnesium glycinate 300–400 mg elemental/day, taken in the evening: Magnesium is a cofactor for 300+ enzymatic reactions including those in the TCA cycle and glycolysis. Deficiency — estimated in 48% of the U.S. population — produces impaired neuronal excitability, elevated NMDA receptor activity, and cognitive symptoms including brain fog and attention lapses. Glycinate form preferred for absorption versus oxide (≈80% vs ≈4% bioavailability).
• Sleep (non-negotiable prerequisite): No stack compensates for less than 7 hours. Adenosine clearance, glymphatic waste removal, and synaptic homeostasis during sleep cannot be supplemented. Sleep debt produces more severe cognitive impairment than any supplement deficiency studied to date.

Tier 2 — Amplification (add after 4 weeks of stable Tier 1):

• KSM-66 ashwagandha 600 mg/day: The Choudhary 2017 RCT used 300 mg twice daily for 8 weeks. The Chandrasekhar 2012 trial used 300 mg high-concentration extract once daily. Both schedules are viable. Effects on cortisol and anxiety begin within 2–4 weeks; cognitive outcomes in the Choudhary trial were significant at 8 weeks.
• Lion’s mane 1,000 mg/day: Use standardized extract (>30% beta-glucans). Effects from NGF stimulation are slow — the Mori 2009 trial showed significant effects at 8 weeks, not 2. Don’t evaluate before that threshold. Add this only after Tier 1 and KSM-66 are stable, so you can isolate its contribution.
• L-theanine 200 mg with caffeine (if you already use caffeine): The 4:1 theanine:caffeine ratio is the best-supported acute cognitive combination in the published literature — consistent improvement in attention and working memory in healthy adults with reduced caffeine-associated anxiety. This is additive to the Tier 1 stack, not a standalone.

What This Stack Won’t Do — and What to Skip

Several popular “cognitive enhancer” categories lack the evidence to make either tier:

• Racetams (piracetam, aniracetam, noopept): No published RCTs in healthy adults with any recognized cognitive endpoint. Human pharmacokinetic data is poorly established for most compounds in this class. Animal data is interesting but hasn’t translated to human trials.
• High-dose B vitamin complexes for “brain energy”: Supraphysiological B vitamin doses have no established cognitive benefit in healthy adults without documented deficiency. The VITACOG trial showed cognitive benefit in adults with high baseline homocysteine — not in those with normal levels.
• Proprietary nootropic blends with undisclosed amounts: You’re typically paying for caffeine and multiple active compounds — none at clinically relevant doses. No way to verify dosing or identify what’s working.
• High-stimulant combinations: Anything above 200 mg caffeine plus synephrine plus yohimbine risks elevated cortisol and worsens the same axis that ashwagandha is trying to modulate. These combinations are actively counterproductive to the stack’s mechanism.

Who Benefits Most

The evidence is strongest for:

• Adults 35+ experiencing cognitive fatigue: NAD+ decline is biologically meaningful by this point. This population also tends to have higher cortisol loads from professional and family demands, making the ashwagandha component particularly relevant.
• High-stress knowledge workers: If your baseline cortisol is chronically elevated — identifiable by poor sleep, afternoon energy crashes, difficulty unwinding — the HPA-modulating effect of KSM-66 is likely the highest-leverage intervention in this stack.
• People with magnesium deficiency: Common in populations eating predominantly processed food. Correcting deficiency alone often produces measurable improvement in mental clarity within 2–3 weeks. Signs include night cramps, poor sleep quality, and anxiety.
• Athletes and people with high training loads: High exercise volume increases both NAD+ demand and cortisol output simultaneously. Both NMN and KSM-66 have relevant evidence in this population. See how to build a circadian-aligned morning routine around these compounds.

This stack has a weaker evidence base in healthy adults in their 20s without sleep debt, chronic stress, or metabolic issues. That population lacks the deficits the stack is designed to address, and expected effect sizes are smaller.

Practical Takeaways

• Add compounds one at a time, at least 4 weeks apart — you need to identify what’s working and what isn’t.
• Use a standardized cognitive test (Cambridge Brain Sciences, N-back app, or simple reaction time test) to establish a baseline before starting. Subjective “feeling” of focus is unreliable as a metric.
• The Choudhary 2017 ashwagandha results were measured at 8 weeks. Don’t evaluate this compound’s cognitive effects before that threshold.
• NMN morning timing is mechanistically supported — take it within 30–60 minutes of waking to align with the NAMPT circadian expression peak.
• Magnesium glycinate evening dosing serves two purposes simultaneously: addressing potential deficiency and supporting sleep quality through GABA-A agonism — which reinforces the sleep foundation this stack depends on.
• L-theanine is the highest-evidence acute add-on if you already use caffeine. The 200 mg dose with your regular coffee is low-cost and low-risk.

Bottom Line

The most evidence-supported focus stack builds from metabolic substrates upward: NMN for neuronal NAD+ and mitochondrial efficiency, magnesium glycinate for enzymatic function and sleep quality, KSM-66 ashwagandha for cortisol reduction and neuroprotection, and lion’s mane as a neurotrophic amplifier. This approach lacks the immediate subjective punch of stimulant stacks but addresses the biological reasons focus declines — and the effects compound over weeks and months rather than wearing off by afternoon. Honest caveat: most RCT evidence is in older adults or stressed populations. Expected effect sizes in healthy young adults with no identifiable deficits are smaller than what’s reported in those trials.

References

1. Yoshino M, et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.” Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. “Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men.” npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. “Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.” Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. “Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners.” J Int Soc Sports Nutr. 2021;18(1):54. [Source]
5. Gomes AP, et al. “Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging.” Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. “The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase.” Nutrients. 2023;15(3):755. [Source]

---

---